Abstract
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the incidence and prevalence of heart disease in the United States is expected to increase significantly over the next decade.
This volume of the Geriatric Medicine series will look at the mechanisms involved in the pathology of the various types of cardiovascular diseases and the specific molecular processes that define these diseases. It will also explore current treatment modalities for hypertension, congestive heart failure, arteriosclerosis, and myocardial infarction, including ﾟ-adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, vasodilators, inotropic drugs and anti-arrhythmics, as well as various devices used to treat congestive heart failure.
It also looks at the new and emerging research and development efforts into the discovery of advanced therapeutic products that address these diseases, including the latest in biotechnological approaches and cell-based therapeutics, as well as new devices, including heart jackets and ventricular patches. We will investigate and discuss the latest in progress towards clinical development of biopharmaceuticals that may be introduced over the next decade for the treatment of cardiovascular disease at its most basic levels.
The report will look at the demographics of the aging United States population, the expected incidence and prevalence of cardiovascular disease of different types, and the United States markets for these therapeutics, currently estimated at over $6.1 billion, that are expected grow around these populations.
Chapter One: Executive Summary
- Background
- Scope and Methodology
- Size and Growth of Market
- Market Trends and Factors
Chapter Two: Introduction
- Background
- Population Demographics
- Epidemiology and Pathology
- Hypertension
- Atherosclerosis
- Congestive Heart Failure
Chapter Three: Cardiovascular Therapeutics
- Background
- Current Approaches to Cardiovascular Disease Therapy
- Patient Education
- Exercise
- Diet
- Pharmaceutical Approaches
- Hypertension
- Diuretics
- ﾟ-Adrenergic Blockers
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Calcium Channel Blockers
- Angiotensin II Receptor Antagonists
- Atherosclerosis
- Fibric Acid Derivatives
- HMG-CoA Reductase Inhibitors
- Bile Acid Sequestrants
- Nicotinic Acid
- Congestive Heart Failure
- Anti-Arrhythmic Drugs
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Antagonists
- a/ﾟ-Adrenergic Blockers
- Diuretics
- Inotropic Drugs
- Vasodilators
- Device Approaches to Congestive Heart Failure
- Pacemakers
- Implantable Cardioverters/Defibrillators
- Ventricular Assist Devices
- Emerging Therapeutic Approaches
- Hypertension
- Diuretics
- ﾟ-Adrenergic Blockers
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Calcium Channel Blockers
- Angiotensin II Receptor Antagonists
- Others
- Atherosclerosis
- Fibric Acid Derivatives
- HMG-CoA Reductase Inhibitors
- Bile Acid Sequestrants
- Nicotinic Acid
- Others
- Congestive Heart Failure
- Anti-Arrhythmic Drugs
- Antihypertensive Drugs
- Inotropic Drugs
- Vasodilators
- Biotechnology
- Immunoglobulins
- Parvalbumin
- Myoblasts
- Stem Cells (Cardiomyocytes)
- Autoregeneration
- Gene Therapy
- Devices
- Heart Jackets
- Heart Pumps
- Resynchronization Systems
- Ventricular Patches
Chapter Four: Market Analysis
- Market Size and Growth
- Overview
- Hypertension
- Atherosclerosis
- Congestive Heart Failure
- Competitive Outlook
- Overview
- Pharmaceuticals
- Hypertension
- Atherosclerosis
- Congestive Heart Failure
- Congestive Heart Failure Devices
- Market Trends
Chapter Five: Company Profiles
- Overview
- Abbott Laboratories
- Abiomed
- Acorn Cardiovascular
- Actelion, Ltd.
- Arrow International
- AstraZeneca
- Aventis
- Bioheart, Inc.
- Bristol-Myers Squibb
- Cardioenergetics
- CV Therapeutics
- GenVec, Inc.
- Geron Corporation
- GlaxoSmithKline
- Guidant Corporation
- Medigene AG
- Medtronic, Inc.
- Merck & Co.
- Micromed Technology, Inc.
- Myocor, Inc.
- Myogen
- Novartis
- Parke-Davis (Pfizer)
- Pfizer, Inc.
- St. Jude Medical
- Sankyo Pharma
- Somanetics Corporation
- Texas Biotechnology Corporation
- Thoratec Corporation
- Wyeth
Chapter Six: Conclusion and Strategic Implications
Appendix A: Company Names and Addresses
医薬品
その他のカテゴリ
FAQ